Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
20
PTPI Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
3.98%
Day range:
$0.0080 - $0.0090
52-week range:
$0.0075 - $16.2500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.19x
P/B ratio:
0.13x
Volume:
245.3K
Avg. volume:
222.6K
1-year change:
-99.91%
Market cap:
$428.2K
Revenue:
$5.1M
EPS (TTM):
-$36.58
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Petros Pharmaceuticals, Inc. has 312400% upside to fair value with a price target of -- per share.
PTPI vs. S&P 500
-
Over the past 5 trading days, Petros Pharmaceuticals, Inc. has underperformed the S&P 500 by -12.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Petros Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Petros Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Petros Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Petros Pharmaceuticals, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Petros Pharmaceuticals, Inc. reported earnings per share of -$0.03.
Enterprise value:
-5.6M
EV / Invested capital:
-1.68x
Price / LTM sales:
0.19x
EV / EBIT:
--
EV / Revenue:
-7.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$195.4K
Return On Assets:
-107.56%
Net Income Margin (TTM):
-1852.34%
Return On Equity:
-55.57%
Return On Invested Capital:
-789%
Operating Margin:
-148.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7M | $1.7M | $725.4K | -- | -- | |
| Gross Profit | $1.2M | $439.4K | -$195.4K | -- | -- | |
| Operating Income | -$9.8M | -$6M | -$6M | -$1.2M | -$990.7K | |
| EBITDA | -$6.3M | -$5.2M | -$5.3M | -$1.2M | -$990.7K | |
| Diluted EPS | -$6.21 | -$609.45 | -$36.58 | -$333.60 | -$0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.4M | $18.8M | $24.4M | $10.7M | $6.1M | |
| Total Assets | $52M | $37.7M | $38.9M | $20.7M | $6.1M | |
| Current Liabilities | $33.5M | $7.9M | $8.1M | $12.6M | $2.8M | |
| Total Liabilities | $34.2M | $17M | $31.9M | $17.6M | $2.8M | |
| Total Equity | $17.8M | $20.7M | $7.1M | $3.1M | $3.4M | |
| Total Debt | $2.2M | $10M | $8.5M | $7.2M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.9M | -- | -$4.8M | -$771.2K | -$1.1M | |
| Cash From Investing | -- | -- | -$24.6K | -$19.1K | -- | |
| Cash From Financing | $13.7M | -- | $7M | -$2.8M | -$117.3K | |
| Free Cash Flow | -$6.9M | -- | -$4.9M | -$790.3K | -$1.1M | |
PTPI
Sector
Market Cap
$428.2K
$27.9M
Price % of 52-Week High
0.05%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-427.42%
-1.55%
1-Year Price Total Return
-99.91%
-17.49%
Beta (5-Year)
2.445
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0094
200-day SMA
Sell
Level
$0.2864
Bollinger Bands (100)
Sell
Level
0.0111 - 0.0311
Chaikin Money Flow
Sell
Level
-366.6M
20-day SMA
Sell
Level
$0.0109
Relative Strength Index (RSI14)
Sell
Level
27.1915
ADX Line
Sell
Level
34.3152
Williams %R
Buy
Level
-93.9759
50-day SMA
Sell
Level
$0.0151
MACD (12, 26)
Sell
Level
-0.0019
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-305.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-15.3913)
Sell
CA Score
(Annual)
Level (-4.2423)
Buy
Beneish M-Score
(Annual)
Level (-2.6783)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (13.8446)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, PTPI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTPI average analyst price target in the past 3 months is --.
-
Where Will Petros Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Petros Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Petros Pharmaceuticals, Inc.?
Analysts are divided on their view about Petros Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Petros Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Petros Pharmaceuticals, Inc.'s Price Target?
The price target for Petros Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PTPI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Petros Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PTPI?
You can purchase shares of Petros Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Petros Pharmaceuticals, Inc. shares.
-
What Is The Petros Pharmaceuticals, Inc. Share Price Today?
Petros Pharmaceuticals, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Petros Pharmaceuticals, Inc.. Yesterday, Petros Pharmaceuticals, Inc. closed at $0.0080 per share.
-
How To Buy Petros Pharmaceuticals, Inc. Stock Online?
In order to purchase Petros Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PTPI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PTPI
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
0.13x
1.81x
Price / LTM sales
0.19x
1.59x
Growth Metrics
PTPI
Sector
Revenue growth
-5.87%
4.6%
Earnings growth
99.99%
10.88%
Revenue (5-year growth)
-19.98%
6.45%
Earnings forecast
-$0.29
-$0.21
Profitability
PTPI
Sector
Profitability FY 2024
$1.1M
$3.6M
Return on invested capital
-789%
-31.84%
Return on assets
-107.56%
-27.96%
Return on equity
-55.57%
-37.63%
Earnings Date
Last Earnings Date
Dec
30
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
PTPI
Sector
Total cash
$6.1M
$26.3M
Short term investments
--
$25.7M
Total assets
$10.6M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 36.69% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.26% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
